Literature DB >> 29339391

Intrapulmonary Pharmacokinetics of Lascufloxacin in Healthy Adult Volunteers.

Hidetoshi Furuie1, Sayoko Tanioka2, Keiko Shimizu3, Shigeru Manita3, Masaharu Nishimura4, Hisao Yoshida5.   

Abstract

This study was performed to investigate the intrapulmonary penetration of lascufloxacin in humans. Thirty healthy adult male Japanese subjects, allocated into five groups, received lascufloxacin in a single oral dose of 75 mg. Bronchoalveolar lavage and blood sampling were performed simultaneously in each subject at 1, 2, 4, 6, or 24 h after administration, and lascufloxacin concentrations in plasma, epithelial lining fluid, and alveolar macrophages were determined. Lascufloxacin was rapidly distributed to the epithelial lining fluid with a time to maximum drug concentration (Tmax) of 1 h, which was identical to that in plasma. The maximum concentration of drug (Cmax) values in plasma, epithelial lining fluid, and alveolar macrophages were 0.576, 12.3, and 21.8 μg/ml, respectively. The corresponding area under the concentration-time curve from 0 to 24 h (AUC0-24) values were 7.67, 123, and 325 μg · h/ml. The mean drug concentrations in the epithelial lining fluid and alveolar macrophages were much higher than those in plasma at all time points examined, and the average site-to-free plasma concentration ratios fell within the ranges of 57.5 to 86.4 and 71.0 to 217, respectively. Drug levels in epithelial lining fluid and alveolar macrophages exceeded the MIC90 values for common respiratory pathogens. (This study was registered at JAPIC under registration number JapicCTI-142547.).
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  drug penetration; lascufloxacin; quinolones

Mesh:

Substances:

Year:  2018        PMID: 29339391      PMCID: PMC5913947          DOI: 10.1128/AAC.02169-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.

Authors:  Keith A Rodvold; Jomy M George; Liz Yoo
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

2.  Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy.

Authors:  J M Andrews; D Honeybourne; G Jevons; N P Brenwald; B Cunningham; R Wise
Journal:  J Antimicrob Chemother       Date:  1997-10       Impact factor: 5.790

3.  Comparative bronchoalveolar concentrations of ciprofloxacin and lomefloxacin following oral administration.

Authors:  D R Baldwin; R Wise; J M Andrews; M Gill; D Honeybourne
Journal:  Respir Med       Date:  1993-11       Impact factor: 3.415

4.  Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes.

Authors:  P Schüler; K Zemper; K Borner; P Koeppe; T Schaberg; H Lode
Journal:  Eur Respir J       Date:  1997-05       Impact factor: 16.671

5.  In Vitro Activities and Spectrum of the Novel Fluoroquinolone Lascufloxacin (KRP-AM1977).

Authors:  Ryuta Kishii; Yuko Yamaguchi; Masaya Takei
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

6.  Interactions between quinolone antibiotics and phospholipid membrane for prediction of alveolar macrophage uptake in vitro.

Authors:  Jin Sun; Yoshiharu Deguchi; Ji-Min Chen; Ru-Hua Zhang; Kazuhiro Morimoto
Journal:  Acta Pharmacol Sin       Date:  2002-05       Impact factor: 6.150

7.  P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.

Authors:  Julien Brillault; Whocely Victor De Castro; Thomas Harnois; Alain Kitzis; Jean-Christophe Olivier; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

8.  Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects.

Authors:  Hidetoshi Furuie; Yutaka Saisho; Takayoshi Yoshikawa; Jingoro Shimada
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

9.  Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults.

Authors:  Blair Capitano; Holly M Mattoes; Eric Shore; Aidan O'Brien; Sidney Braman; Chistina Sutherland; David P Nicolau
Journal:  Chest       Date:  2004-03       Impact factor: 9.410

Review 10.  Epidemiology of Mycoplasma pneumoniae Infections in Japan and Therapeutic Strategies for Macrolide-Resistant M. pneumoniae.

Authors:  Tsutomu Yamazaki; Tsuyoshi Kenri
Journal:  Front Microbiol       Date:  2016-05-23       Impact factor: 5.640

View more
  4 in total

1.  In Vitro Mechanistic Study of the Distribution of Lascufloxacin into Epithelial Lining Fluid.

Authors:  Kouhei Ohya; Junichi Takano; Shigeru Manita
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 2.  Antimicrobial Resistance in ESKAPE Pathogens.

Authors:  David M P De Oliveira; Brian M Forde; Timothy J Kidd; Patrick N A Harris; Mark A Schembri; Scott A Beatson; David L Paterson; Mark J Walker
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

Review 3.  Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms.

Authors:  Despoina Koulenti; Elena Xu; Andrew Song; Isaac Yin Sum Mok; Drosos E Karageorgopoulos; Apostolos Armaganidis; Sotirios Tsiodras; Jeffrey Lipman
Journal:  Microorganisms       Date:  2020-01-30

Review 4.  Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update.

Authors:  Emily N Drwiega; Keith A Rodvold
Journal:  Clin Pharmacokinet       Date:  2021-10-15       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.